Myovant Sciences Ltd. Common Shares (MYOV): Price and Financial Metrics


Myovant Sciences Ltd. Common Shares (MYOV): $19.48

0.44 (+2.31%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

MYOV Stock Summary

  • Myovant Sciences Ltd's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than merely 6.74% of US listed stocks.
  • MYOV's price/sales ratio is 49.8; that's higher than the P/S ratio of 94.5% of US stocks.
  • MYOV's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of merely 5.16% of US stocks.
  • If you're looking for stocks that are quantitatively similar to Myovant Sciences Ltd, a group of peers worth examining would be CDXS, BCYC, KPTI, BLDP, and SILC.
  • Visit MYOV's SEC page to see the company's official filings. To visit the company's web site, go to myovant.com.

MYOV Stock Price Chart Interactive Chart >

Price chart for MYOV

MYOV Price/Volume Stats

Current price $19.48 52-week high $30.90
Prev. close $19.04 52-week low $11.04
Day low $18.49 Volume 693,300
Day high $19.64 Avg. volume 955,589
50-day MA $21.39 Dividend yield N/A
200-day MA $20.11 Market Cap 1.77B

Myovant Sciences Ltd. Common Shares (MYOV) Company Bio


Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women’s health diseases and other endocrine-related disorders. The company was founded in 2016 and is based in Hamilton, Bermuda.


MYOV Latest News Stream


Event/Time News Detail
Loading, please wait...

MYOV Latest Social Stream


Loading social stream, please wait...

View Full MYOV Social Stream

Latest MYOV News From Around the Web

Below are the latest news stories about Myovant Sciences Ltd that investors may wish to consider to help them evaluate MYOV as an investment opportunity.

Myovant (MYOV), Pfizer Start Dosing in Relugolix Combo Study

Myovant (MYOV) and Pfizer (PFE) initiate dosing in the phase III SERENE study evaluating the contraceptive efficacy of the relugolix combination tablet.

Yahoo | April 13, 2021

Myovant Sciences and Pfizer Announce First Participant Dosed in Phase 3 SERENE Study Evaluating Contraceptive Efficacy of Once-Daily Relugolix Combination Tablet

SERENE is a Phase 3 single-arm, open-label study evaluating the contraceptive efficacy of investigational relugolix combination tablet in sexually active, healthy women ages 18-35 yearsContraceptive potential of relugolix combination tablet supported by prior Phase 1 study that demonstrated 100% ovulation inhibition Data would support a potential indication of pregnancy prevention for women treated with relugolix combination tablet, if approved BASEL, Switzerland and NEW YORK, April 12, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced that the first participant has been dosed in the Phase 3 SERENE study evaluating the contraceptive efficacy of relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 ...

Yahoo | April 12, 2021

Myovant Sciences Announces European Medicines Agency Validation of Marketing Authorization Application for Relugolix for the Treatment of Advanced Prostate Cancer

If approved, relugolix would be the first and only oral androgen deprivation therapy for advanced prostate cancer in EuropeRelugolix is FDA-approved and currently available in the U.S. under the trade name ORGOVYX™ Pfizer has an exclusive option to commercialize relugolix in oncology outside of the U.S. and Canada, excluding certain Asian countries, with a decision expected in the first half of 2021 BASEL, Switzerland, March 29, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for relugolix for the treatment of advanced prostate cancer. The validation of the application confirms the submission is suf...

Yahoo | March 29, 2021

Robert W. Baird Stick to Their Buy Rating for Myovant Sciences By Investing.com

Robert W. Baird Stick to Their Buy Rating for Myovant Sciences

Investing.com | March 25, 2021

U.S. Uterine Fibroid Treatment Market | Blue Endo, Boston Scientific Corporation, CooperSurgical, Inc., KARL STORZ SE & Co. KG, Myovant Sciences (Sumitovant Biopharma Ltd.), Halt Medical, Inc., LiNA Medical USA, Merit Medical Systems

U.S. Uterine Fibroid Treatment Market report is an in-depth analysis study offered which explains necessary aspects like competition, segmentation, and regional growth in excessive detail. As a part of competitive analysis, the analysis study includes thorough company identification of leading

OpenPR | March 23, 2021

Read More 'MYOV' Stories Here

MYOV Price Returns

1-mo -10.64%
3-mo -6.62%
6-mo 23.14%
1-year 58.12%
3-year 1.46%
5-year N/A
YTD -29.47%
2020 77.96%
2019 -5.42%
2018 29.83%
2017 1.61%
2016 N/A
Page generated in 0.9205 seconds.